2Urgio K L,locher JL,Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc, 2000,48(4) :37. 被引量：1
3Ttiasson A, Blaakser J, Hoye K,et al. Tolterodine Scandinavian Study Group. Simplified bladder training augments the effectiveness of tolterodine in pateients with an overactiCe bladder,BJU Int, 2003,91 : 54-60. 被引量：1
4Carat-Barredo JM,Cafaratfi-Sfulcirri J. Treatment Of bladder instability (non-neurogenic hyperactive bladder)in children,with toherodine. Actas Urol Eap,2004,25:199-125. 被引量：1
6DOBREK L, JUSZCZAK K, WYCZOLKOWSKI M, et al. Current management and future perspectives of overactive blad der (OAB) pharmacotherapy[J]. Acta Pol Pharm, 2011,68(6) 807-821. 被引量：1
7MALHOTRA B,GANDELMAN K,SACHSE R, et al. The de- sign and development of fesoterodine as a prodrug of 5-hydroxy- methyl tolterodine(5-HMT),the active metabolite of 101 terod- ine[J]. Curr Med Chem,2009,16(33):4481-4489. 被引量：1
8HOMMA Y, YOSHIDA M, SEKI N, et al. Symptom assess- ment tool for overactive bladder syndrome -- overactive bladder symptom score[J]. Urology, 2006 ,68(2) : 318-323. 被引量：1
9MATZA LS,THOMPSON CL,KRASNOW J, et al. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ) [J]. Neurourol Urodyn,2005,24(3) :215-225. 被引量：1
10LAM S, HILAS O. Pharmacologic management of overactive bladder[J]. Clin Interv Aging,2007, 2(3) : 337-345. 被引量：1
